JP2020517615A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020517615A5 JP2020517615A5 JP2019556626A JP2019556626A JP2020517615A5 JP 2020517615 A5 JP2020517615 A5 JP 2020517615A5 JP 2019556626 A JP2019556626 A JP 2019556626A JP 2019556626 A JP2019556626 A JP 2019556626A JP 2020517615 A5 JP2020517615 A5 JP 2020517615A5
- Authority
- JP
- Japan
- Prior art keywords
- scleroderma
- cells
- polynucleotide
- vector
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762488207P | 2017-04-21 | 2017-04-21 | |
| US62/488,207 | 2017-04-21 | ||
| US201762512382P | 2017-05-30 | 2017-05-30 | |
| US62/512,382 | 2017-05-30 | ||
| PCT/US2018/028551 WO2018195410A1 (en) | 2017-04-21 | 2018-04-20 | Delivery of autologous cells comprising matrix metalloproteinase for treatment of scleroderma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020517615A JP2020517615A (ja) | 2020-06-18 |
| JP2020517615A5 true JP2020517615A5 (cg-RX-API-DMAC7.html) | 2023-06-16 |
Family
ID=63856118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556626A Ceased JP2020517615A (ja) | 2017-04-21 | 2018-04-20 | 硬皮症の処置のための、マトリックス金属タンパク質分解酵素を含む自己由来細胞の送達 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20200129561A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3612554A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2020517615A (cg-RX-API-DMAC7.html) |
| KR (1) | KR102544139B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110770249B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018254555A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3060099A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201909440UA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018195410A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4380601A4 (en) * | 2021-08-06 | 2025-06-25 | Trujillo, Charles, Nathan | SYSTEM AND METHOD FOR TREATING OR PREVENTING RESPIRATORY FAILURE WITH AEROSOLIZED COLLAGENASE |
| CN114921446B (zh) * | 2022-06-08 | 2025-08-29 | 宁波市健康口腔医学研究院 | 一种口腔癌标志物线性表位融合肽及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9930768D0 (en) * | 1999-12-29 | 2000-02-16 | Pfizer Ltd | Composition |
| WO2009116860A1 (en) * | 2008-03-17 | 2009-09-24 | Vereniging Het Nederlands Kanker Instituut | Markers providing prognosis of metastasis among cancer patients |
| JP5649589B2 (ja) * | 2009-03-06 | 2015-01-07 | ハロザイム インコーポレイテッド | マトリックスメタロプロテアーゼ1の温度感受性突然変異体およびその使用 |
| EP2550359B1 (en) * | 2010-03-23 | 2017-08-09 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| CN103370340B (zh) * | 2010-12-02 | 2016-08-31 | 庆北大学校产学协力团 | 包含dhFas-1结构域和MMP底物的融合肽及其在预防和治疗类风湿性关节炎中的应用 |
| US9283287B2 (en) * | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| WO2013152351A2 (en) * | 2012-04-06 | 2013-10-10 | The Trustees Of Columbia University In The City Of New York | Fusion polypeptides and methods of use thereof |
| EP4050020A1 (en) * | 2014-03-11 | 2022-08-31 | University of Florida Research Foundation, Inc. | Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease |
| SG11201702295UA (en) * | 2014-09-22 | 2017-04-27 | Intrexon Corp | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| AU2016334401A1 (en) * | 2015-10-10 | 2018-04-26 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
-
2018
- 2018-04-20 CN CN201880039742.1A patent/CN110770249B/zh not_active Expired - Fee Related
- 2018-04-20 JP JP2019556626A patent/JP2020517615A/ja not_active Ceased
- 2018-04-20 AU AU2018254555A patent/AU2018254555A1/en not_active Abandoned
- 2018-04-20 CA CA3060099A patent/CA3060099A1/en active Pending
- 2018-04-20 KR KR1020197034204A patent/KR102544139B1/ko active Active
- 2018-04-20 WO PCT/US2018/028551 patent/WO2018195410A1/en not_active Ceased
- 2018-04-20 EP EP18788049.7A patent/EP3612554A4/en not_active Withdrawn
- 2018-04-20 US US16/606,293 patent/US20200129561A1/en not_active Abandoned
- 2018-04-20 SG SG11201909440U patent/SG11201909440UA/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7590724B2 (ja) | 炎症性腸疾患の治療薬 | |
| Nissen et al. | Increased turnover of arterial collagen in hypertensive rats. | |
| CN1496271B (zh) | 伴随有aop-1基因或aop-1的表达减少的疾病的治疗方法以及该疾病的治疗药 | |
| ES2622877T3 (es) | Tratamiento para la obesidad | |
| CN102766204B (zh) | 胰高血糖素样肽-1突变体多肽及其制备方法和其应用 | |
| Qi et al. | Tissue inhibitor of metalloproteinases-3 peptides inhibit angiogenesis and choroidal neovascularization in mice | |
| US20190358144A1 (en) | Compositions comprising peptide wkdeagkplvk | |
| US10213488B2 (en) | Delivery of therapeutic agents by a collagen binding protein | |
| KR20120101617A (ko) | 알부민과 레티놀 결합 단백질의 융합 단백질 | |
| AU2013202269A1 (en) | Compositions and methods for the treatment of fibrosis and fibrotic diseases | |
| JP6573293B2 (ja) | 炎症性疾患の予防または治療用ペプチド及びこの用途 | |
| Zafar et al. | Adeno associated viral vector-mediated expression of somatostatin in rat hippocampus suppresses seizure development | |
| Goldspink et al. | Growth factors, muscle function and doping | |
| WO2004108748A3 (en) | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses | |
| Zhong et al. | Krüppel-like transcription factor 14 alleviates alveolar epithelial cell senescence by inhibiting endoplasmic reticulum stress in pulmonaryfibrosis | |
| Nagler et al. | Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone | |
| CN111944035B (zh) | Fgf4及其应用 | |
| AU2014233219B2 (en) | Methods for treatment of nephrotic syndrome and related conditions | |
| AU2008347208B2 (en) | Treatment of fibroses and liver disorders | |
| CN110770249B (zh) | 递送包含基质金属蛋白酶的自体细胞用于治疗硬皮病 | |
| US20030228283A1 (en) | Preventing secondary lymphedema with VEGF-D DNA | |
| Herrmann et al. | Transforming growth factor-α enhances stem cell-mediated postischemic myocardial protection | |
| KR20220015638A (ko) | 염증성 질환의 예방 또는 치료용 조성물 및 이의 용도 | |
| US20180066027A1 (en) | Protamine in treatment of neuronal injuries | |
| JP2008231036A (ja) | ポリペプチドを有効成分とする自己免疫性皮膚疾患治療薬 |